Regeneron and Intellia expand gene editing partnership
vchal/iStock via Getty Images

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intellia Therapeutics (NASDAQ:NTLA) on Tuesday announced they expanded their existing research collaboration for gene editing therapies to focus on additional targets in neurological and muscular diseases.
The expanded deal combines Regeneron (REGN) viral vector delivery technologies and Intellia (NTLA) gene modification technologies, including its CRISPR/Cas9 platform.

Per the terms, the duo will initially research two in vivo non-liver targets, and each company will have the chance to lead potential development and commercialization for candidates aimed at one target.
The company that doesnât lead the program can enter a co-development and co-commercialization agreement for the target.

In June 2020, Regeneron (REGN) and Intellia (NTLA) expanded their collaboration to develop CRISPR/Cas9-based therapeutics for five additional in vivo liver targets, including hemophilia A and B products.



More on Intellia, Regeneron, etc.

Intellia Therapeutics: Massive OpEx Begin To Weigh On HAE Prospects
Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)
Regeneron nabs FDA priority review for lymphoma therapy
Regeneron, Sanofi label expansion for Dupixent under FDA priority review